"We'll show direct costs and direct expenses," D'Amelio said. In 2015 those statements will be even more granular, he said.
D'Amelio said the company would need three years of audited financials prior to making a decision to split off or spinoff any of the three units. He confirmed on the call that those financials would be prospective. So don't expect a complete break-off of any of the three units from the parent company until 2017.
Of course, that doesn't mean a Valeant Pharmaceuticals (VRX) couldn't come along before then and acquire one of them. Watch this space.
-- Written by Pamela Taulbee In New York